1. Home
  2. IDYA vs EXPO Comparison

IDYA vs EXPO Comparison

Compare IDYA & EXPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$31.94

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Logo Exponent Inc.

EXPO

Exponent Inc.

HOLD

Current Price

$72.65

Market Cap

3.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDYA
EXPO
Founded
2015
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.4B
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
IDYA
EXPO
Price
$31.94
$72.65
Analyst Decision
Strong Buy
Buy
Analyst Count
16
3
Target Price
$51.21
$90.50
AVG Volume (30 Days)
757.3K
517.0K
Earning Date
05-19-2026
05-07-2026
Dividend Yield
N/A
1.70%
EPS Growth
61.90
8.76
EPS
N/A
1.58
Revenue
$218,710,000.00
$558,514,000.00
Revenue This Year
N/A
$12.52
Revenue Next Year
$97.58
$8.54
P/E Ratio
N/A
$46.21
Revenue Growth
3024.43
4.05
52 Week Low
$13.45
$63.81
52 Week High
$39.28
$87.88

Technical Indicators

Market Signals
Indicator
IDYA
EXPO
Relative Strength Index (RSI) 45.48 52.36
Support Level $29.15 $70.17
Resistance Level $33.64 $72.99
Average True Range (ATR) 1.47 3.15
MACD 0.10 0.20
Stochastic Oscillator 59.47 43.12

Price Performance

Historical Comparison
IDYA
EXPO

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About EXPO Exponent Inc.

Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.

Share on Social Networks: